Genome-wide study of methotrexate clearance replicates SLCO1B1.

PubWeight™: 1.17‹?› | Rank: Top 10%

🔗 View Article (PMC 3567337)

Published in Blood on December 11, 2012

Authors

Laura B Ramsey1, John C Panetta, Colton Smith, Wenjian Yang, Yiping Fan, Naomi J Winick, Paul L Martin, Cheng Cheng, Meenakshi Devidas, Ching-Hon Pui, William E Evans, Stephen P Hunger, Mignon Loh, Mary V Relling

Author Affiliations

1: Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.

Associated clinical trials:

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | NCT00137111

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia | NCT00005596

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia | NCT00005585

Articles citing this

Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56

A 50-year journey to cure childhood acute lymphoblastic leukemia. Semin Hematol (2013) 1.32

Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration. J Clin Oncol (2015) 1.26

The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther (2014) 1.17

Inherited genetic variation in childhood acute lymphoblastic leukemia. Blood (2015) 1.09

The intestinal absorption of folates. Annu Rev Physiol (2014) 0.94

The membrane transport and polyglutamation of pralatrexate: a new-generation dihydrofolate reductase inhibitor. Cancer Chemother Pharmacol (2013) 0.88

Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group. Clin Pharmacol Ther (2015) 0.88

Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: why still at the bench level? Eur J Clin Pharmacol (2013) 0.85

Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease. Public Health Genomics (2014) 0.84

Development of Human Membrane Transporters: Drug Disposition and Pharmacogenetics. Clin Pharmacokinet (2016) 0.81

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia. Clin Pharmacol Ther (2016) 0.81

Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Rev (2015) 0.79

Persistent pharmacokinetic challenges to pediatric drug development. Front Genet (2014) 0.79

SLCO1B1 Variants and Angiotensin Converting Enzyme Inhibitor (Enalapril) -Induced Cough: a Pharmacogenetic Study. Sci Rep (2015) 0.79

Uptake carriers and oncology drug safety. Drug Metab Dispos (2013) 0.79

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer. Pharmacogenomics J (2016) 0.78

Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy. AAPS J (2015) 0.78

The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combos. Hum Vaccin Immunother (2013) 0.77

Association of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia. PLoS One (2014) 0.77

Mathematical modeling of folate metabolism. Wiley Interdiscip Rev Syst Biol Med (2013) 0.76

Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis. Pharmacogenomics J (2014) 0.75

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol (2014) 0.75

Preventing and Managing Toxicities of High-Dose Methotrexate. Oncologist (2016) 0.75

Non-infectious chemotherapy-associated acute toxicities during childhood acute lymphoblastic leukemia therapy. F1000Res (2017) 0.75

Pharmacogenomics in Pediatric Oncology: Review of Gene-Drug Associations for Clinical Use. Int J Mol Sci (2016) 0.75

High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma (2013) 0.75

MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy. Pharmgenomics Pers Med (2017) 0.75

Genome Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality. Clin Cancer Res (2017) 0.75

Articles cited by this

Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23

The structure of haplotype blocks in the human genome. Science (2002) 50.88

METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics (2010) 21.21

SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 5.49

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90

SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet Genomics (2006) 2.66

Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res (2011) 2.52

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol (2009) 2.47

Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J Clin Oncol (2009) 2.20

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev (2011) 2.08

Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood (2011) 2.04

LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology (2001) 2.02

Genome-wide association meta-analysis for total serum bilirubin levels. Hum Mol Genet (2009) 1.96

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med (1986) 1.67

Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial. J Clin Oncol (2011) 1.60

Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood (2007) 1.52

Global analysis of genetic variation in SLCO1B1. Pharmacogenomics (2008) 1.47

Down's syndrome in childhood acute lymphoblastic leukemia: clinical characteristics and treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Münster Group. Leukemia (1998) 1.44

ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol (2012) 1.39

Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 1.39

Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther (2011) 1.14

Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia. J Pediatr (1987) 1.10

Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukaemia. Lancet (1984) 1.10

Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet Genomics (2006) 1.08

Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells. PLoS Comput Biol (2010) 1.07

CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol (2003) 1.06

In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharm Res (2011) 1.01

Flavopiridol pharmacogenetics: clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One (2010) 0.99

Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. J Clin Pharmacol (2008) 0.97

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics (2008) 0.94

Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol (1994) 0.92

Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia. Haematologica (2010) 0.90

Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford) (2003) 0.86

Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Leukemia (2005) 0.83

Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population. J Pharm Sci (2011) 0.78

Articles by these authors

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature (2007) 17.68

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83

Treatment of acute lymphoblastic leukemia. N Engl J Med (2006) 11.30

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med (2009) 10.54

BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Large-scale sequence analysis of avian influenza isolates. Science (2006) 9.87

Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med (2009) 7.95

Acute lymphoblastic leukemia. N Engl J Med (2004) 7.83

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood (2008) 5.49

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol (2009) 5.22

Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol (2012) 5.08

JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A (2009) 4.98

Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. Nat Genet (2011) 4.93

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89

Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89

Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41

Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet (2009) 4.35

The tumor lysis syndrome. N Engl J Med (2011) 4.29

Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood (2004) 4.21

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol (2009) 4.20

Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med (2004) 4.16

Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med (2004) 4.15

Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood (2010) 4.00

Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood (2006) 3.91

Gene expression profiling of pediatric acute myelogenous leukemia. Blood (2004) 3.77

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol (2010) 3.76

CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature (2011) 3.72

Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71

Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood (2010) 3.66

Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med (2003) 3.57

The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43

Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40